Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the industrial enzyme, bioenergy, bio-based chemical and biopharmaceutical industries, announced that its research and development center in the Netherlands is a participant in the HealthBread Project, a new multidisciplinary research program that has been awarded approximately one million Euro from the European Community's Seventh Framework Programme (FP7).
